Citadel Advisors
GBT

Citadel Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Citadel Advisors’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-65,500
Closed -$4.46M – 16073
2022
Q3 		$4.46M Buy
65,500
+6,000
+10% +$331K ﹤0.01% 4067
2022
Q2 		$1.9M Sell
59,500
-15,400
-21% -$451K ﹤0.01% 5641
2022
Q1 		$2.6M Sell
74,900
-18,400
-20% -$550K ﹤0.01% 5503
2021
Q4 		$2.73M Buy
93,300
+25,300
+37% +$784K ﹤0.01% 5524
2021
Q3 		$1.73M Sell
68,000
-45,800
-40% -$1.35M ﹤0.01% 6730
2021
Q2 		$3.98M Buy
113,800
+41,400
+57% +$1.62M ﹤0.01% 4945
2021
Q1 		$2.95M Sell
72,400
-2,700
-4% -$124K ﹤0.01% 5486
2020
Q4 		$3.25M Buy
75,100
+11,700
+18% +$577K ﹤0.01% 4454
2020
Q3 		$3.5M Sell
63,400
-11,300
-15% -$718K ﹤0.01% 3714
2020
Q2 		$4.72M Buy
74,700
+20,900
+39% +$1.43M ﹤0.01% 3173
2020
Q1 		$2.75M Sell
53,800
-426,300
-89% -$28.6M ﹤0.01% 3614
2019
Q4 		$38.2M Buy
480,100
+283,900
+145% +$16.8M 0.02% 957
2019
Q3 		$9.52M Buy
196,200
+29,200
+17% +$1.52M ﹤0.01% 2276
2019
Q2 		$8.78M Buy
167,000
+54,900
+49% +$3.15M ﹤0.01% 2340
2019
Q1 		$5.93M Buy
112,100
+44,400
+66% +$2.18M ﹤0.01% 2756
2018
Q4 		$2.78M Buy
67,700
+14,800
+28% +$555K ﹤0.01% 3646
2018
Q3 		$2.01M Sell
52,900
-116,500
-69% -$5.16M ﹤0.01% 4400
2018
Q2 		$7.66M Buy
169,400
+95,700
+130% +$4.36M ﹤0.01% 2230
2018
Q1 		$3.56M Buy
+73,700
New +$4.11M ﹤0.01% 2894
2017
Q4 		– Sell
-7,000
Closed -$217K – 8600
2017
Q3 		$217K Sell
7,000
-37,500
-84% -$1.05M ﹤0.01% 6570
2017
Q2 		$1.22M Buy
44,500
+11,000
+33% +$327K ﹤0.01% 3813
2017
Q1 		$1.23M Buy
33,500
+16,500
+97% +$416K ﹤0.01% 3709
2016
Q4 		$246K Sell
17,000
-10,900
-39% -$192K ﹤0.01% 5967
2016
Q3 		$643K Buy
27,900
+8,100
+41% +$154K ﹤0.01% 4467
2016
Q2 		$328K Buy
+19,800
New +$399K ﹤0.01% 5085

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's GBT Position: Q4 2022 in Review

Citadel Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 51,397 shares — an estimated $3.5M sold.

Citadel Advisors first reported a position in GBT in Q3 2016 and held it in 24 quarters. The position peaked at $68.1M in Q1 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Citadel Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 51,397 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $3.5M.
  • Citadel Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 24 quarters.
  • Citadel Advisors's Global Blood Therapeutics, Inc. position peaked at $68.1M in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.